Posted on Leave a comment

2025 at EBiSC: new iPSCs, new partners, continued excellence.

As we finish our second year operating independently and sustainably, we want to take a moment to reflect on the progress we have made in 2025 and to thank our teams, partners and collaborators who have contributed to making it a success. It has been a year of hard work, collaboration and teamwork, fed by our continued commitment to building a sustainable, long-term resource for the scientific community.

Expanding the EBiSC collection with new disease relevant iPSC lines

This year, we were pleased to welcome a number of new iPSC lines into the EBiSC collection, strengthening the diversity of iPSCs we can provide for disease-modelling and translational research. Newly added lines include models for Alzheimer’s disease, Angelman syndrome, and congenital muscular dystrophy (CMD) — each representing an important and fast moving area of iPSC research.

These additions broaden the scope of iPS cells and data which we are able to make available to researchers worldwide and reflect our commitment to continuing to provide a secure, sustainable and long-term home for iPSC lines generated across diverse research projects.

Improved access through new international distribution partnerships

To improve how we share resources to researchers worldwide, EBiSC has established new delivery partnerships to support regional and international shipping across Australia, New Zealand, Japan and the USA. These local partners help reduce delivery times, streamline logistics and lower shipping costs, ensuring that EBiSC iPSCs reach laboratories more efficiently than ever.

We look forward to strengthening these relationships in 2025 and improving access for new and existing users across additional regions.

A strong year for banking, quality control and data management

Behind every iPSC line in the EBiSC catalogue, a huge amount of work is invested into cell banking, quality control, documentation and data management. This is possible thanks to the strong partnership between Fraunhofer UK and Fraunhofer IBMT, who jointly operate and maintain the EBiSC collection. The shared commitment from our teams in the UK and Germany to quality assured cell banking and QC, robust and secure cryostorage and FAIR data principles ingrained into our IT infrastructure, ensure the longevity, sustainability and reliability of the EBiSC resource for years to come. A huge thank you to all involved!

Looking Ahead

As we prepare for the new year, we remain dedicated to expanding the collection, enabling access to high-quality datasets and supporting the global iPSC research community through collaboration, cell and service provision and development of new resources, tools and models.

From all of us at EBiSC, thank you for your continued engagement and support throughout 2025.

We wish you a restful winter break and a bright start to 2026.

Merry Christmas and Happy New Year!

Posted on Leave a comment

EBiSC expands access in Japan through partnership with KAC!

We’re pleased to announce that KAC Co., Ltd. is now the official partner supporting the promotion and delivery of EBiSC iPSC lines in Japan.
KAC brings extensive experience supplying cell lines, primary cells, culture media, sera and research reagents to laboratories across Japan. Through this collaboration, researchers will benefit from simplified local access, improved logistics and dedicated support when ordering from the EBiSC catalogue of 1000 high-quality iPSC lines covering more than 45 disease areas.

This partnership strengthens EBiSC’s global network and supports our mission to make well-characterised iPSC resources accessible to researchers worldwide.

🧬 Explore EBiSC’s iPSC collection: www.ebisc.org
📩 Contact KAC: https://lnkd.in/eXZi8XP8
🌐 www.kacnet.co.jp

Posted on Leave a comment

Isogenic LRRK2 iPSC lines now available via EBiSC!

Understanding the molecular drivers of Parkinson’s disease is essential for developing effective treatments and the LRRK2 gene remains one of the most significant contributors to both inherited and sporadic forms of the condition.
To investigate this, researchers led by Dr Sally Cowley at the Oxford Parkinson’s Disease Centre have shared a set of LRRK2 gene-edited iPSC lines, including isogenic knockouts and disease-associated variants. These models were generated from high-quality parental lines originally developed through the StemBANCC collaboration, demonstrating the continued impact of large, multi-partner initiatives in building resources which can be shared and used by all researchers.


These iPSC lines are fully quality-controlled and come with comprehensive metadata, enabling robust and reproducible studies of LRRK2 function, cellular pathology, and therapeutic targets.

🔬 Explore these LRRK2 iPSC lines in the EBiSC catalogue: https://ebisc.org/search?q=&hpscreg-genes=%5B%22LRRK2%22%5D&product-status=%5B%5D&gene-edited=true

Posted on Leave a comment

Big news for biomedical researchers in Australia and New Zealand!

We’re excited to announce that CellBank Australia is now the official distributor of the EBiSC stem cell collection for Australia and New Zealand — making it easier than ever for researchers across Oceania to access 950+ high-quality iPSC lines covering more than 45 disease areas, including cardiovascular, neurological, and metabolic disorders.

This partnership expands EBiSC’s global reach, ensuring that our validated iPSC lines and pre-differentiated cells are available to support research in disease modelling, drug discovery, and regenerative medicine across the region.

Operated by the Children’s Medical Research Institute (CMRI), CellBank brings 18+ years of expertise in authenticated cell lines and quality control services. The collaboration is further strengthened by CMRI’s Stem Cell and Organoid Facility, advancing 3D organoid models and translational research.

📧 cellbank@cmri.org.au

🌐 https://www.cellbankaustralia.com/cell-lines-for-distribution/

Posted on Leave a comment

Congenital Muscular Dystrophy collection now available via EBiSC.

Skeletal muscle laminopathies are rare genetic disorders caused by pathogenic mutations in the LMNA gene, leading to progressive muscle weakness and other severe symptoms. This study by researchers at UCL demonstrates the use of iPSCs carrying LMNA mutations to model these conditions, offering valuable insights into disease mechanisms and therapeutic opportunities.

We’re pleased to share that CureCMD have now made the iPSC lines featured in this research available through EBiSC. These lines provide an essential tool for researchers studying laminopathies and advancing treatments for these challenging disorders.

Access the collection and learn more here. Let’s drive innovation in skeletal muscle disease research!

https://ebisc.org/search?q=CMDi

#Laminopathies #SkeletalMuscleResearch #iPSC #EBiSC #Genetics #DiseaseModeling #RareDiseases

Posted on Leave a comment

Focal Segmental Glomerulosclerosis (FSGS) iPSCs and clinical data

We’re happy to share that the iPSC lines from the study “Generation of 20 Human Induced Pluripotent Stem Cell Lines from Patients with Focal Segmental Glomerulosclerosis (FSGS)” are available through EBiSC!

These iPSC lines, derived from patients with FSGS, provide a valuable resource for studying kidney disease mechanisms and testing potential therapies. Detailed clinical data is available upon request for researchers looking to deepen their understanding of FSGS.

Explore the iPSC lines and access data via EBiSC here to drive forward your nephrology research.

#FSGS #iPSC #KidneyResearch #EBiSC #GeneticResearch #DiseaseModeling #Nephrology #RegenerativeMedicine

Posted on Leave a comment

New publication on EBiSC-NEUR1 neurons!

We’re thrilled to see the paper “Measurements of Neurite Extension and Nucleokinesis in an iPSC-Derived Model System Following Microtubule Perturbation” published, showcasing the power of EBiSC iPSC-derived neurons.

This study highlights how iPSC technology can be used to model and measure key cellular processes like neurite extension and nucleokinesis, offering valuable insights into neurodevelopmental diseases. It’s exciting to see how EBiSC-generated iPSC lines are contributing to cutting-edge research that deepens our understanding of cellular dynamics and disease mechanisms.

https://pubmed.ncbi.nlm.nih.gov/39602292

#iPSC #Neurodegeneration #Neuroscience #EBiSC #DiseaseModeling #StemCellResearch #Neurodevelopment